Indazole vitronectin receptor antagonist pharmaceuticals
    5.
    发明授权
    Indazole vitronectin receptor antagonist pharmaceuticals 失效
    吲唑玻连蛋白受体拮抗剂药物

    公开(公告)号:US06322770B1

    公开(公告)日:2001-11-27

    申请号:US09281207

    申请日:1999-03-30

    IPC分类号: A61K5100

    摘要: The present invention d ribs novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

    摘要翻译: 本发明d排除下式的新型化合物:可用于癌症的诊断和治疗,对患者的肿瘤成像的方法,以及在患者中治疗癌症的方法。 本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。 药物由与血管发生期间上调的受体结合的靶向部分,任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。 可成像部分是伽马射线或正电子发射放射性同位素,磁共振成像造影剂,X射线造影剂或超声造影剂。

    Quinolone vitronectin receptor antagonist pharmaceuticals
    6.
    发明授权
    Quinolone vitronectin receptor antagonist pharmaceuticals 有权
    喹诺酮玻连蛋白受体拮抗剂药物

    公开(公告)号:US06524553B2

    公开(公告)日:2003-02-25

    申请号:US09281209

    申请日:1999-03-30

    IPC分类号: A61B5055

    摘要: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

    摘要翻译: 本发明描述了新的下式化合物:可用于癌症的诊断和治疗,对患者肿瘤成像的方法,以及治疗患者癌症的方法。 本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。 药物由与血管发生期间上调的受体结合的靶向部分,任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。 可成像部分是伽马射线或正电子发射放射性同位素,磁共振成像造影剂,X射线造影剂或超声造影剂。

    Radiolabelled complexes of ester-substituted diaminethiols
    7.
    发明授权
    Radiolabelled complexes of ester-substituted diaminethiols 失效
    酯取代的二氨基硫醇的放射性标记复合物

    公开(公告)号:US5688485A

    公开(公告)日:1997-11-18

    申请号:US999705

    申请日:1992-12-31

    摘要: This invention relates to compounds and methods for use in determining renal function by means of scintigraphic urography. More specifically, this invention relates to radionuclide complexes of ester-substituted diaminethiols, radiopharmaceutical compositions comprising said complexes, kits for the preparation of said compositions, and a method of using said compositions for examining renal function. Compounds of this invention have the formula: ##STR1## wherein the various groups are as defined herein.

    摘要翻译: 本发明涉及通过闪烁照相术确定肾功能的化合物和方法。 更具体地,本发明涉及酯取代的二氨基硫醇的放射性核素配合物,包含所述复合物的放射性药物组合物,用于制备所述组合物的试剂盒,以及使用所述组合物检查肾功能的方法。 本发明的化合物具有下列通式:本文所述。